News
VKTX
--
0.00%
--
Diacylglycerol O Acyltransferase 1 Market Share 2021 with latest research report and Growth, Size by 2024 Market Analysis, Trends, Key Vendors, Drivers and Forecast
Apr 16, 2021 (The Expresswire) -- Global Diacylglycerol O Acyltransferase 1 Market 2021 industry research report gives Advancement strategies and plans are...
The Express Wire · 5d ago
Global Diacylglycerol O Acyltransferase 1 Market Outlook, Industry Analysis and Prospect 2021-2026
Apr 15, 2021 (Heraldkeepers) -- COMTEX_384481098/2582/2021-04-15T07:59:21 Is there a problem with this press release? Contact the source provider Comtex at...
Heraldkeepers · 5d ago
Trends and Opportunities in Nonalcoholic Steatohepatitis (NASH) Market, Forecast To 2025
Apr 09, 2021 (Market Insight Reports) -- This research service provides a strategic analysis of the Stem Cell Banking Outsourcing Market 2021-2025. Learn how...
Market Insight Reports · 04/09 10:29
Bumbershoot Holdings: “Viking Therapeutics (VKTX) Struggled Right Off the Bat”
Bumbershoot Holdings LP, an investment management firm, published its fourth quarter 2020 investor letter – a copy of which can be downloaded here. Bumbershoot Holdings L.P. generated a negative gross return of -6.61% for the full-year 2020, while its S&P ...
Insider Monkey · 04/08 16:49
Viking Therapeutics to Present at 20th Annual Needham Virtual Healthcare Conference
, /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, , Ph.D...
PR Newswire - PRF · 04/07 20:05
Novel Cancer Therapy Phase 3 Trial Expects To Be Completed Shortly
The following article is sponsored by Actinium Pharmaceuticals, Inc. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only.
Benzinga · 04/06 13:07
Adrenoleukodystrophy (ALD) - Pipeline Analysis, Industry Report, Growth, Price, Trends and Forecast 2020-2025
Comserve · 04/06 05:59
Diacylglycerol O Acyltransferase 1 Market Latest Research On Industry Growth, Trends, Top Players, & Key Regions By 2027
Apr 05, 2021 (Market Insight Reports) -- The latest report as Diacylglycerol O Acyltransferase 1 Market acknowledges Size, Application Segment, Type,...
Market Insight Reports · 04/05 11:17
Global Adrenoleukodystrophy (ALD) Market Outlook, Industry Analysis and Prospect 2019
Apr 05, 2021 (Heraldkeepers) -- COMTEX_383912838/2582/2021-04-05T05:07:46 Is there a problem with this press release? Contact the source provider Comtex at...
Heraldkeepers · 04/05 09:07
Global Non-alcoholic Steatohepatitis Market 2020 Growth by Opportunities, Application, Current Trend and Forecast by 2025
Apr 01, 2021 (CDN Newswire via Comtex) -- The report entitled Global Non-alcoholic Steatohepatitis Market Growth 2020-2025 eases the process of understanding...
CDN Newswire · 04/01 09:23
Cancer Anorexia-Cachexia Syndrome Drug Market Segmentation, Application, Trends, Opportunity and Forecast 2020 - 2027 by Ameco Research
pune, India, Fri, 26 Mar 2021 02:08:28 / Comserve Inc. / -- A new research report titled "Global Cancer Anorexia-Cachexia Syndrome Drug Market" successfully...
Comserve · 03/26 06:11
Gilead (GILD) Expands NASH Collaboration With Novo Nordisk
Zacks.com · 03/19 14:06
Viking Therapeutics to Participate at Upcoming Investor Conferences
, /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate in thr...
PR Newswire - PRF · 03/04 21:30
Intercept's (ICPT) Q4 Loss Wider than Expected, Sales Miss
Zacks.com · 02/26 19:43
Diacylglycerol O Acyltransferase 1 Market Size, Growth, Share 2021 Report to 2026: Industry Insights, Company Overview and Investment, Market and Top Manufacturers
The Express Wire · 02/23 04:49
Cancer Anorexia-Cachexia Syndrome Drug Market Analysis, Size, Share, Trends and Forecast 2020-2027
pune, India, Mon, 22 Feb 2021 02:38:56 / Comserve Inc. / -- Cancer Anorexia-Cachexia Syndrome Drug market is segmented by Type, and by Application. Players,...
Comserve · 02/22 07:40
Corbus Pharmaceuticals Holdings Inc. stock rises Friday, outperforms market
marketwatch.com · 02/19 21:38
Viking Therapeutics (VKTX) Receives a Rating Update from a Top Analyst
In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Viking Therapeutics (VKTX), with a price target of $15.00.
SmarterAnalyst · 02/19 15:05
Analysts Are Bullish on Top Healthcare Stocks: Viking Therapeutics (VKTX), Milestone Scientific (MLSS)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Viking Therapeutics (VKTX) and Milestone Scientific (MLSS)
SmarterAnalyst · 02/19 12:33
Webull provides a variety of real-time VKTX stock news. You can receive the latest news about Viking Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company's clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. VK5211 is a non-steroidal selective androgen receptor modulator (SARM). Its second program is focused on the development of orally available small molecule thyroid hormone receptor beta agonists. Its two molecules are VK2809 and VK0214. VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid beta receptor that is entering Phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. It is developing VK0214 for the treatment of X-linked adrenoleukodystrophy (X-ALD). It has a pipeline with approximately three additional programs targeting metabolic diseases and anemia.